| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1044763909 |
| P356 | DOI | 10.2165/00003495-200767110-00004 |
| P698 | PubMed publication ID | 17661528 |
| P50 | author | Georg Maschmeyer | Q88881628 |
| Oliver A Cornely | Q57062280 | ||
| P2093 | author name string | Antje Haas | |
| P2860 | cites work | Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever | Q28216366 |
| Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 | ||
| 1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid | Q28249155 | ||
| Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans | Q28265703 | ||
| Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome | Q28276727 | ||
| Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial | Q28277029 | ||
| Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia | Q28284944 | ||
| Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) | Q28298468 | ||
| Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial | Q28359772 | ||
| Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis | Q28377349 | ||
| Plasma (1-->3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes | Q29038934 | ||
| Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan | Q30577215 | ||
| Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial | Q30596268 | ||
| Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients | Q30887333 | ||
| Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial | Q31125591 | ||
| Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group | Q31372000 | ||
| Aspergillosis case-fatality rate: systematic review of the literature | Q31918085 | ||
| Mortality and costs of acute renal failure associated with amphotericin B therapy | Q32068576 | ||
| Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study | Q33342242 | ||
| Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan | Q33592749 | ||
| Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group | Q33854646 | ||
| False positivity for Aspergillus antigenemia with amoxicillin-clavulonic acid | Q33859221 | ||
| Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America | Q33894472 | ||
| Current status of nonculture methods for diagnosis of invasive fungal infections | Q33906498 | ||
| A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan | Q33980368 | ||
| Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study | Q33983629 | ||
| Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group | Q34002098 | ||
| Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy | Q34033598 | ||
| Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution | Q34069443 | ||
| Use of real-time PCR to process the first galactomannan-positive serum sample in diagnosing invasive aspergillosis | Q34073294 | ||
| 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer | Q34114674 | ||
| A study of consecutive autopsies in a medical ICU : a comparison of clinical cause of death and autopsy diagnosis | Q34137012 | ||
| An overview of fungal infections | Q34162712 | ||
| Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies | Q34162934 | ||
| Hospital infection control in hematopoietic stem cell transplant recipients | Q34213683 | ||
| Epidemiology of fungal infections in solid organ transplant patients | Q34294864 | ||
| Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlle | Q40596481 | ||
| Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors | Q40604160 | ||
| Intensive intravenous amphotericin B for prophylaxis of systemic fungal infections. Results of a prospective controlled pilot study in acute leukemia patients | Q40619933 | ||
| A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients | Q40645972 | ||
| Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study | Q40701026 | ||
| Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections | Q40708990 | ||
| Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis | Q40734608 | ||
| The efficacy of itraconazole against systemic fungal infections in neutropenic patients: A randomised comparative study with amphotericin B | Q40754163 | ||
| Invasive pulmonary aspergillosis in adult acute leukemia: clinical clues to its diagnosis | Q40816306 | ||
| Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia | Q40847963 | ||
| Comparative analysis of prognostic indicators of aspergillosis in haematological malignancies and HIV infection. | Q40913472 | ||
| Infectious complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma. | Q40931570 | ||
| Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature | Q41542963 | ||
| Burn wound infections: current status | Q41694816 | ||
| Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients | Q41998776 | ||
| A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. | Q42048818 | ||
| In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis | Q42068116 | ||
| Prevention of amphotericin-B-induced nephrotoxicity by loading with sodium chloride: a report of 1291 days of treatment with amphotericin B without renal failure | Q42191679 | ||
| Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. | Q42285296 | ||
| NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis | Q42599568 | ||
| Use of galactomannan enzyme immunoassay for diagnosis of invasive aspergillosis in a tertiary-care center over a 12-month period | Q42911728 | ||
| Plasmalyte as a cause of false-positive results for Aspergillus galactomannan in bronchoalveolar lavage fluid | Q42912557 | ||
| Recovery of filamentous fungi from water in a paediatric bone marrow transplantation unit. | Q43341736 | ||
| Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection | Q43416427 | ||
| Cyclophosphamide metabolism is affected by azole antifungals | Q43530745 | ||
| Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters | Q43560592 | ||
| Congestive heart failure associated with itraconazole | Q43638251 | ||
| Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients | Q43648084 | ||
| Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. | Q43732838 | ||
| Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. | Q43788508 | ||
| Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial | Q43801360 | ||
| Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis | Q43864353 | ||
| Aspergillosis due to carpet contamination. | Q43874390 | ||
| Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis | Q43952852 | ||
| Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign | Q44023091 | ||
| Prophylactic administration of liposomal amphotericin B is superior to treatment in a murine model of invasive aspergillosis after hematopoietic cell transplantation | Q44045004 | ||
| Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials | Q44062340 | ||
| Concentrations of airborne Aspergillus compared to the incidence of invasive aspergillosis: lack of correlation | Q44160630 | ||
| Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin | Q44304226 | ||
| Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study | Q44396642 | ||
| Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin | Q44469440 | ||
| Influence of high-efficiency particulate air filtration on mortality and fungal infection: a rebuttal | Q44479147 | ||
| Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies | Q44519647 | ||
| Treatment of fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). | Q44589098 | ||
| Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study | Q44595697 | ||
| Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B. | Q44602927 | ||
| Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants | Q44606439 | ||
| False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. | Q44688423 | ||
| Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients | Q44691631 | ||
| Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients | Q44733428 | ||
| False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. | Q44785839 | ||
| Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies | Q44785842 | ||
| Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients | Q44807745 | ||
| Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study | Q44832013 | ||
| Itraconazole versus fluconazole for antifungal prophylaxis. | Q44833684 | ||
| Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases | Q45015455 | ||
| False-positive Aspergillus galactomannan antigen test results | Q45015468 | ||
| Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity | Q45066131 | ||
| New cause for false-positive results with the Pastorex Aspergillus antigen latex agglutination test. | Q37133728 | ||
| 10 year review of invasive aspergillosis detected at necropsy | Q37141726 | ||
| False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment | Q37597610 | ||
| Fungal burn wound infection. A 10-year experience | Q37621397 | ||
| Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment | Q38679942 | ||
| Fungal contamination of food in hematology units. | Q39462272 | ||
| In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. | Q39651019 | ||
| Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis | Q39652561 | ||
| Opportunistic fungal infection of the burn wound with phycomycetes and Aspergillus. A clinical-pathologic review | Q40062077 | ||
| Nosocomial aspergillosis: a retrospective review of airborne disease secondary to road construction and contaminated air conditioners | Q40244250 | ||
| Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers | Q40346459 | ||
| Efficacy and toxicity of intermediate-dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematological malignancies | Q40384862 | ||
| A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II. | Q40475785 | ||
| Usefulness of sequential Aspergillus galactomannan antigen detection combined with early radiologic evaluation for diagnosis of invasive pulmonary aspergillosis in patients undergoing allogeneic stem cell transplantation. | Q40475979 | ||
| Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study | Q40497134 | ||
| Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation | Q40513418 | ||
| Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies | Q40514264 | ||
| Direct detection of angioinvasive pulmonary aspergillosis in immunosuppressed patients: preliminary results with high-resolution 16-MDCT angiography | Q40514353 | ||
| Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia | Q40524745 | ||
| Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy | Q40541356 | ||
| Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeits | Q40550138 | ||
| Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). | Q40550143 | ||
| Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients | Q40572100 | ||
| A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients | Q40577742 | ||
| Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients | Q40585861 | ||
| Autologous peripheral blood stem cell transplant in patients previously diagnosed with invasive aspergillosis | Q40596372 | ||
| High level of recovery of fungi from water and dialysate in haemodialysis units | Q74008136 | ||
| Fungal colonization of air filters from hospitals | Q74026068 | ||
| Invasive aspergillosis | Q74492548 | ||
| Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche | Q74579178 | ||
| Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation | Q74579207 | ||
| Pulmonary Aspergillus colonization in humans and its impact on management of critically ill patients | Q77228210 | ||
| Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia | Q77299304 | ||
| Early infections in patients undergoing bone marrow or blood stem cell transplantation--a 7 year single centre investigation of 409 cases | Q77366207 | ||
| Prediction of invasive pulmonary aspergillosis from colonisation of lower respiratory tract before marrow transplantation | Q77530137 | ||
| Invasive aspergillosis in neutropenic patients: rapid neutrophil recovery is a risk factor for severe pulmonary complications | Q77829261 | ||
| Variable number of tandem repeats of TNF receptor type 2 promoter as genetic biomarker of susceptibility to develop invasive pulmonary aspergillosis | Q79506947 | ||
| Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis | Q79804764 | ||
| Interleukin-10 promoter polymorphism as risk factor to develop invasive pulmonary aspergillosis | Q79829012 | ||
| Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries | Q79895605 | ||
| Long-term CT follow-up in 40 non-HIV immunocompromised patients with invasive pulmonary aspergillosis: kinetics of CT morphology and correlation with clinical findings and outcome | Q79966887 | ||
| Detection of Aspergillus galactomannan by enzyme immunoabsorbent assay in recipients of allogeneic hematopoietic stem cell transplantation: a prospective study | Q80008313 | ||
| Delayed ABLC prophylaxis after allogeneic stem-cell transplantation | Q80146502 | ||
| Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1-->3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological | Q80174046 | ||
| Kinetics of galactomannan in surgical patients receiving perioperative piperacillin/tazobactam prophylaxis | Q80192309 | ||
| Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation | Q80231148 | ||
| Invasive aspergillosis in critically ill patients without malignancy | Q80269940 | ||
| Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance | Q80312940 | ||
| Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients | Q80536933 | ||
| Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia | Q81134376 | ||
| Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation | Q81398889 | ||
| Galactomannan and the diagnosis of invasive aspergillosis | Q83163314 | ||
| A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients | Q83919477 | ||
| Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003) | Q83938057 | ||
| Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies | Q34301513 | ||
| Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections | Q34352100 | ||
| Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation | Q34368144 | ||
| Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases | Q34404335 | ||
| Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. | Q34430636 | ||
| Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. | Q34455633 | ||
| Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience | Q34455699 | ||
| Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis | Q34514484 | ||
| Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients | Q34553509 | ||
| Safety and tolerability of caspofungin acetate in the treatment of fungal infections | Q34746958 | ||
| Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies | Q34977257 | ||
| Summary: future directions in antifungal therapy | Q35027508 | ||
| Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients | Q35076852 | ||
| In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis | Q35091285 | ||
| Clinical pharmacology of antifungal compounds | Q35129039 | ||
| Itraconazole resistance in Aspergillus fumigatus | Q35136791 | ||
| Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. | Q35219729 | ||
| Detection of Aspergillus DNA in cerebrospinal fluid from patients with cerebral aspergillosis by a nested PCR assay | Q35220840 | ||
| Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). | Q35298777 | ||
| Aspergillus antigen testing in bone marrow transplant recipients | Q35396243 | ||
| Fatal haemoptysis associated with invasive pulmonary aspergillosis treated with high-dose amphotericin B and granulocyte-macrophage colony-stimulating factor (GM-CSF). | Q35529418 | ||
| Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature | Q35761396 | ||
| Update on the treatment of cerebral aspergillosis | Q35763586 | ||
| Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis | Q35789251 | ||
| A consensus on fungal polymerase chain reaction diagnosis?: a United Kingdom-Ireland evaluation of polymerase chain reaction methods for detection of systemic fungal infections | Q35790217 | ||
| Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of th | Q35849045 | ||
| Utility of Aspergillus antigen detection in specimens other than serum specimens | Q35951605 | ||
| Pulmonary infections after bone marrow transplantation: high-resolution CT findings in 111 patients | Q36240071 | ||
| Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. | Q36349776 | ||
| Campath-1H induction and the incidence of infectious complications in adult renal transplantation | Q36371927 | ||
| The influence of high-efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients: a systematic review | Q36451064 | ||
| Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies | Q36526353 | ||
| Detection and identification of fungal pathogens in blood by using molecular probes. | Q36544360 | ||
| Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. | Q54619719 | ||
| Epidemiological study of invasive pulmonary aspergillosis in a haematology unit by molecular typing of environmental and patient isolates of Aspergillus fumigatus. | Q54671391 | ||
| Prospective clinical evaluation of a LightCycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematolog | Q54723179 | ||
| Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area | Q56941303 | ||
| Environmental sampling for aspergilli during building construction on a hospital site | Q57135750 | ||
| Trends in Risk Profiles for and Mortality Associated with Invasive Aspergillosis among Liver Transplant Recipients | Q57569380 | ||
| TLR1 and TLR6 Polymorphisms Are Associated with Susceptibility to Invasive Aspergillosis after Allogeneic Stem Cell Transplantation | Q57908265 | ||
| Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients | Q58865962 | ||
| Voriconazole Prophylaxis in Lung Transplant Recipients | Q59230762 | ||
| Galactomannan Does Not Precede Major Signs on a Pulmonary Computerized Tomographic Scan Suggestive of Invasive Aspergillosis in Patients with Hematological Malignancies | Q59308866 | ||
| Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation | Q59312591 | ||
| The Effect of Prophylactic Fluconazole on the Clinical Spectrum of Fungal Diseases in Bone Marrow Transplant Recipients with Special Attention to Hepatic Candidiasis: An Autopsy Study of 355 Patients | Q59512024 | ||
| Epidemiology ofAspergillusInfections in a Large Cohort of Patients Undergoing Bone Marrow Transplantation | Q59512032 | ||
| Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection | Q60029223 | ||
| Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis | Q61758327 | ||
| Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections | Q61758371 | ||
| Multiple-Triazole–Resistant Aspergillosis | Q63914862 | ||
| Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group | Q64132952 | ||
| Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis | Q66841111 | ||
| Aspergillus Infection of the Burn Wound | Q66944772 | ||
| Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response | Q67561741 | ||
| Aspergillus infections in cancer patients. Association with fireproofing materials in a new hospital | Q67770550 | ||
| Endemic and epidemic aspergillosis associated with in-hospital replication of Aspergillus organisms | Q68043033 | ||
| Nosocomial fungal infection during hospital renovation | Q69817516 | ||
| Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients | Q70582486 | ||
| Pulmonary aspergillosis: early diagnosis improves survival | Q70877231 | ||
| Kitchens as a source of Aspergillus niger infection | Q71217133 | ||
| Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia | Q71268640 | ||
| Autologous bone marrow transplantation is feasible in patients with a prior history of invasive pulmonary aspergillosis | Q71299234 | ||
| Fungal prophylaxis with AmBisome in liver and bone marrow transplant recipients: results of two randomized double-blind studies | Q72058165 | ||
| Evolving risk factors for invasive fungal infections--all neutropenic patients are not the same | Q72160665 | ||
| Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia | Q72248781 | ||
| Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients | Q72312612 | ||
| Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer | Q72675254 | ||
| Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis | Q73037373 | ||
| A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group | Q73165218 | ||
| Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia | Q73336907 | ||
| Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules | Q73460720 | ||
| Tolerance and efficacy of Amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients | Q73521812 | ||
| Fungal infection of burn wounds in patients with open and occlusive treatment methods | Q73741246 | ||
| Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study | Q73767268 | ||
| Comparison of premortem clinical diagnoses in critically iII patients and subsequent autopsy findings | Q73892686 | ||
| Surgical management of invasive pulmonary aspergillosis in neutropenic patients | Q73916229 | ||
| Combination antifungal therapy for invasive aspergillosis | Q45096994 | ||
| Postmortem analysis of invasive aspergillosis in a tertiary care hospital | Q45143296 | ||
| Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials | Q45168346 | ||
| Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy | Q45172488 | ||
| Aspergillus antigen in serum, urine and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome | Q45268727 | ||
| Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia | Q45282734 | ||
| Treatment of invasive aspergillosis with itraconazole | Q46380526 | ||
| Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients | Q46421810 | ||
| Study of renal safety in amphotericin B lipid complex-treated patients | Q46421821 | ||
| Lipid formulations of amphotericin B: clinical efficacy and toxicities | Q46460941 | ||
| Choosing a study population for the evaluation of antifungal prophylaxis | Q46486680 | ||
| Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay | Q46503389 | ||
| Usefulness of liposomal amphotericin B for the prophylaxis of fungal infection in solid organ transplant recipients | Q46508942 | ||
| Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study | Q46529531 | ||
| Improved outcome in central nervous system aspergillosis, using voriconazole treatment | Q46585075 | ||
| Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome | Q46758158 | ||
| An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. | Q46844044 | ||
| The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation | Q47612248 | ||
| Intracranial aspergillosis in children successfully treated with antifungal therapy and surgical intervention. | Q48602772 | ||
| Impact of previous aspergillosis on the outcome of bone marrow transplantation | Q49172509 | ||
| Bloodstream infections in organ transplant recipients receiving alemtuzumab: no evidence of occurrence of organisms typically associated with profound T cell depletion | Q50084520 | ||
| Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. | Q51116991 | ||
| Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. | Q51187346 | ||
| Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. | Q51190403 | ||
| Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients. | Q51191494 | ||
| Relationship between environmental fungal contamination and the incidence of invasive aspergillosis in haematology patients. | Q51192022 | ||
| Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. | Q51192216 | ||
| Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. | Q51193013 | ||
| Airborne fungal spore monitoring in a protective environment during hospital construction, and correlation with an outbreak of invasive aspergillosis. | Q51195391 | ||
| Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. French Cooperative Study Group on Aspergillosis in AIDS. | Q51195851 | ||
| Differences in beta-glucan levels in culture supernatants of a variety of fungi. | Q51201410 | ||
| Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. | Q51700168 | ||
| Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. | Q52222221 | ||
| Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. | Q52588180 | ||
| Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. | Q52922198 | ||
| An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. | Q53349495 | ||
| Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. | Q53626853 | ||
| Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. | Q53950594 | ||
| Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. | Q53999286 | ||
| Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. | Q54034991 | ||
| Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. | Q54251450 | ||
| Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients | Q54270865 | ||
| P433 | issue | 11 | |
| P921 | main subject | aspergillosis | Q259626 |
| invasive aspergillosis | Q3625278 | ||
| P304 | page(s) | 1567-1601 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients | |
| P478 | volume | 67 |
| Q90254018 | A Prospective Real-World Study of the Impact of an Antifungal Stewardship Program in a Tertiary Respiratory-Medicine Setting |
| Q35674400 | A novel case of canine disseminated aspergillosis following mating |
| Q33398514 | A role for the unfolded protein response (UPR) in virulence and antifungal susceptibility in Aspergillus fumigatus |
| Q45172325 | A routine method for the quantification of the novel antimycotic drug posaconazole in plasma using liquid chromatography-tandem mass spectrometry |
| Q40768797 | Acute lymphocytic leukemia with superimposed invasive aspergillosis and pneumopericardium successfully treated with voriconazole |
| Q52673294 | Acylhydrazones as Antifungal Agents Targeting the Synthesis of Fungal Sphingolipids. |
| Q55280636 | Additional oxidative stress reroutes the global response of Aspergillus fumigatus to iron depletion. |
| Q37925817 | Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients. |
| Q37263780 | Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions |
| Q35942379 | An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole |
| Q52936136 | Analysis of the clinical features of invasive bronchopulmonary aspergillosis. |
| Q41964909 | Antifungal Treatments Delineate a Correlation between Cathepsins and Cytokines in Murine Model of Invasive Aspergillosis |
| Q37554059 | Antifungal drug resistance: do molecular methods provide a way forward? |
| Q33851401 | Aspergillus colonization in patients with chronic obstructive pulmonary disease |
| Q34637909 | Aspergillus fumigatus AcuM regulates both iron acquisition and gluconeogenesis |
| Q33865358 | Aspergillus fumigatus CalA binds to integrin α5β1 and mediates host cell invasion |
| Q42661479 | Aspergillus fumigatus RasA regulates asexual development and cell wall integrity. |
| Q37200064 | Aspergillus fumigatus: virulence genes in a street-smart mold |
| Q30361624 | Aspergillus infections in transplant and non-transplant surgical patients |
| Q42860155 | Augmenting the activity of antifungal agents against aspergilli using structural analogues of benzoic acid as chemosensitizing agents |
| Q61492723 | Autophagy in the filamentous fungus Aspergillus fumigatus |
| Q37859397 | Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis? |
| Q33754548 | CD8⁺ T-cell counts: an early predictor of risk and mortality in critically ill immunocompromised patients with invasive pulmonary aspergillosis |
| Q51181304 | Characterization and identification of proteases secreted by Aspergillus fumigatus using free flow electrophoresis and MS. |
| Q35157409 | Chinese herbal medicine for myelosuppression induced by chemotherapy or radiotherapy: a systematic review of randomized controlled trials |
| Q53084391 | Chronic necrotizing pulmonary aspergillosis in an immunocompetent patient: report of a rare case. |
| Q37328834 | Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis |
| Q43248816 | Clinical itraconazole-resistant strains of Aspergillus fumigatus, isolated serially from a lung aspergilloma patient with pulmonary tuberculosis, can be detected with real-time PCR method |
| Q35678982 | Combining standard clinical methods with PCR showed improved diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies and prolonged neutropenia |
| Q41649222 | Comparative evaluation of galactomannan test with bronchoalveolar lavage and serum for the diagnosis of invasive aspergillosis in patients with hematological malignancies |
| Q81924114 | Comparison of the value of measurement of serum galactomannan and Aspergillus-specific antibodies in the diagnosis of canine sino-nasal aspergillosis |
| Q38174050 | Connective Tissue Disease-Associated Interstitial Lung Disease: A Focused Review |
| Q38060582 | Current understanding of HOG-MAPK pathway in Aspergillus fumigatus |
| Q37981720 | Current understanding of PTX3 protective activity on Aspergillus fumigatus infection |
| Q40424792 | DNA Barcoding Coupled with High Resolution Melting Analysis Enables Rapid and Accurate Distinction of Aspergillus species |
| Q37463228 | Diagnosis and treatment of aspergillosis in children |
| Q37650317 | Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients. |
| Q90380486 | Diagnostic accuracy of magnetic resonance imaging in the evaluation of pulmonary infections in immunocompromised patients |
| Q38467076 | Differential gene expression in Aspergillus fumigatus induced by human platelets in vitro. |
| Q40735467 | Disseminated aspergillosis causing intestinal failure following colectomy for perforated colitis |
| Q58615893 | Do indoor plants contribute to the aeromycota in city buildings? |
| Q44577469 | Early diagnosis and preemptive therapy of pulmonary mold infections in high-risk patients |
| Q26748172 | Ecology of aspergillosis: insights into the pathogenic potency of Aspergillus fumigatus and some other Aspergillus species |
| Q37936259 | Economic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies |
| Q40562962 | Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. |
| Q53748960 | Enhanced skin deposition and delivery of voriconazole using ethosomal preparations. |
| Q42151650 | Expression turnover profiling to monitor the antifungal activities of amphotericin B, voriconazole, and micafungin against Aspergillus fumigatus |
| Q33867013 | Factors associated with mortality in transplant patients with invasive aspergillosis |
| Q42555868 | Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure |
| Q38202571 | Fungal infections in cancer patients |
| Q40061239 | Galactofuranose antigens, a target for diagnosis of fungal infections in humans |
| Q92525201 | High Efficiency Drug Repurposing Design for New Antifungal Agents |
| Q36933346 | High Intracellular Concentrations of Posaconazole Do Not Impact on Functional Capacities of Human Polymorphonuclear Neutrophils and Monocyte-Derived Macrophages In Vitro |
| Q27003952 | Histone-modifying enzymes, histone modifications and histone chaperones in nucleosome assembly: Lessons learned from Rtt109 histone acetyltransferases |
| Q38268925 | Host genetics of invasive Aspergillus and Candida infections |
| Q41035582 | IL-12 Influence mTOR to Modulate CD8+ T Cells Differentiation through T-bet and Eomesodermin in Response to Invasive Pulmonary Aspergillosis |
| Q28752041 | Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus |
| Q37788693 | Immunogenetics of invasive aspergillosis |
| Q38232197 | Improved treatment of multidrug-resistant bacterial infections: utility of clinical studies. |
| Q35068517 | In vitro analyses of mild heat stress in combination with antifungal agents against Aspergillus fumigatus biofilm |
| Q38202582 | Infection control and prevention considerations |
| Q37791115 | Infectious lesions mimicking central nervous system neoplasms |
| Q64085926 | Intracellular Delivery of Biologically-Active Fungal Metabolite Gliotoxin Using Magnetic Nanoparticles |
| Q43186002 | Intracranial Aspergillus infection associated with an amyloid tumor and lymphoma |
| Q33909352 | Invasive aspergillosis due to Neosartorya udagawae |
| Q41726648 | Invasive aspergillosis in a renal transplant recipient successfully treated with interferon-gamma |
| Q37854719 | Invasive aspergillosis in children with hematological malignancies |
| Q36149359 | Invasive aspergillosis masquerading as catastrophic antiphospholipid syndrome |
| Q83091809 | Invasive pulmonary aspergillosis in patients with HBV-related liver failure |
| Q38987096 | Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis |
| Q41735419 | Lung MRI of invasive fungal infection at 3 Tesla: evaluation of five different pulse sequences and comparison with multidetector computed tomography (MDCT). |
| Q46920534 | Microsecond pulsed magnetic field improves efficacy of antifungal agents on pathogenic microorganisms. |
| Q42213715 | Microwave ablation of a large renal aspergilloma |
| Q37538775 | Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method |
| Q43718029 | Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study |
| Q52649901 | New insights into the clinical characteristics and prognostic factors of pulmonary fungal infections from a retrospective study in Southwestern China. |
| Q59356608 | Pathogenic Fungal Species Associated with Digestive System of (Blattaria: Blattidae) Trapped from Residential Dwellings in Ahvaz City, Southwestern Iran |
| Q37263189 | Patients at high risk of invasive fungal infections: when and how to treat |
| Q47747509 | Pentraxin 3 Gene Polymorphisms and Pulmonary Aspergillosis in Chronic Obstructive Pulmonary Disease Patients |
| Q38880522 | Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections |
| Q33451082 | Pharmacodynamics and pharmacokinetics of micafungin in adults, children and neonate |
| Q37389541 | Pinpointing prognostic indicators of fungal infections in transplant patients |
| Q26827758 | Pneumonia in the neutropenic cancer patient |
| Q37154746 | Posaconazole : a review of its use in the prophylaxis of invasive fungal infections |
| Q37839071 | Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts |
| Q55188486 | Prevention of Cyclophosphamide-Induced Immunosuppression in Mice with the Antimicrobial Peptide Sublancin. |
| Q41688288 | Prevention of Invasive Aspergillosis in High-Risk Patients: Universal Versus Preemptive, Targeted Treatment |
| Q37657464 | Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question? |
| Q43610568 | Primary aspergilloma and subacute invasive aspergillosis in two AIDS patients |
| Q38222029 | Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. |
| Q48155956 | Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). |
| Q36539892 | Rapid detection of triazole antifungal resistance in Aspergillus fumigatus |
| Q35638993 | Real-time nucleic acid sequence-based amplification to predict the clinical outcome of invasive aspergillosis. |
| Q59089511 | Recent Developments in Inhaled Triazoles Against Invasive Pulmonary Aspergillosis |
| Q36569767 | Redundant synthesis of a conidial polyketide by two distinct secondary metabolite clusters in Aspergillus fumigatus |
| Q42205092 | Relapsed and secondary disease drive the risk profile for invasive aspergillosis prior to stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndrome |
| Q49837757 | Relationship of environmental disturbances and the infectious potential of fungi |
| Q40082354 | Report from the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Infectious Diseases Society of America Joint Conference 2008: Washington, DC, USA, October 25-28, 2008. |
| Q38202574 | Respiratory infections |
| Q37371901 | Respiratory tract infections and pneumonia |
| Q48135433 | Retrospective review of immunocompromised children undergoing skin biopsy for suspected invasive infection: Analysis of factors predictive of invasive mold. |
| Q90265273 | Revealing the Virulence Potential of Clinical and Environmental Aspergillus fumigatus Isolates Using Whole-Genome Sequencing |
| Q34756973 | Secondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease: a retrospective analysis |
| Q53423870 | Serum galactomannan strongly correlates with outcome of invasive aspergillosis in acute leukaemia patients. |
| Q38774244 | Special Issue: Novel Antifungal Drug Discovery |
| Q46142966 | Successful treatment of invasive sphenoidal, pulmonary and intracerebral aspergillosis after multivisceral transplantation |
| Q34385038 | Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis |
| Q52646902 | The Aspergillus fumigatus β-1,3-glucanosyltransferase Gel7 plays a compensatory role in maintaining cell wall integrity under stress conditions. |
| Q95840925 | The Pheromone Module SteC-MkkB-MpkB-SteD-HamE Regulates Development, Stress Responses and Secondary Metabolism in Aspergillus fumigatus |
| Q43132685 | The diagnosis of invasive and noninvasive pulmonary aspergillosis by serum and bronchoalveolar lavage fluid galactomannan assay |
| Q40128466 | The effect of clinical characteristics on the performance of galactomannan and PCR for the diagnosis of invasive aspergillosis in febrile neutropenic patients. |
| Q33613647 | Therapy of murine pulmonary aspergillosis with antibody-alliinase conjugates and alliin. |
| Q58694422 | Tracheobronchial manifestations of Aspergillus infections |
| Q48149197 | Triazole Resistance in Aspergillus spp.: A Worldwide Problem? |
| Q37327092 | Update on the epidemiology and diagnosis of invasive fungal infection. |
| Q40674435 | Use of intravoxel incoherent motion diffusion-weighted MR imaging for assessment of treatment response to invasive fungal infection in the lung |
| Q30583368 | Utility of PCR in diagnosis of invasive fungal infections: real-life data from a multicenter study. |
| Q37099587 | Value of serial quantification of fungal DNA by a real-time PCR-based technique for early diagnosis of invasive Aspergillosis in patients with febrile neutropenia |
| Q39932430 | Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients |
| Q45942598 | [Current status of invasive fungal infections. New diagnostic techniques and antifungal agents]. |
Search more.